medwireNews: Giving semaglutide to folks present process minimally invasive endoscopic sleeve gastroplasty (ESG) could convey weight reduction nearer to that induced by bariatric surgical procedure, exhibits analysis.
The small randomized research, as a consequence of be introduced on the digital Digestive Illness Week 2021, concerned 58 contributors present process ESG, who have been assigned to take semaglutide at a most dose of 1.5 mg/week or placebo, ranging from inside 1 month of the process.
Each teams misplaced weight, however from round 6 months, weight reduction within the semaglutide group started to outstrip that of the placebo group, reaching a mean of 26.7% by the tip of the 11-month follow-up, in contrast with 19.6% amongst these given placebo.
Members within the semaglutide group additionally misplaced a mean 12.69% of their fats mass, whereas the placebo group misplaced a considerably smaller 9.04%, and their common glycated hemoglobin degree was considerably decrease.
Presenting the information to press, Anna Carolina Hoff (Angioskope Brazil, São José dos Campos) famous that the burden loss outcomes achieved with ESG plus semaglutide “method bariatric surgical procedure outcomes.”
However she added that surgical procedure is indicated solely at a excessive BMI, or after comorbidities have developed, and solely 2% of eligible folks bear the process. Against this, she stated, ESG will be carried out at a decrease BMI, making it obtainable to extra folks, together with those that don’t want to bear surgical procedure.
medwireNews is an unbiased medical information service supplied by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, a part of the Springer Nature Group